Biology researchers who developed a drug to treat skin cancer are to receive almost £30 million in funding in order to help treat even more diseases.
The research unit, based at the University of Dundee, was awarded the funding by the UK Government on Thursday, which will allow them to continue their work for another five years.
The Medical Research Council (MRC) and Protein Phosphorylation and Ubiquitylation Unit (PPR) has been a part of the development and clinical approval of more than 40 drugs, and it is hoped that improving the understanding of the processes within cells could be the basis for treating Parkinson’s to Crohn’s and Coeliac disease.
Their work has already delivered a drug that is now widely used to treat melanoma, the most dangerous form of skin cancer, and they have also helped to develop a new drug to treat Parkinson’s disease, which is currently undergoing clinical trials.
The 200-strong scientific staff and students at the university are now using modern technology and biochemistry to explore how signals within the body’s cells are transmitted.
It will receive the funding, allocated by the UK Research and Innovation (UKRI) to bolster its studies in cell biology.
Science and technology secretary Peter Kyle said: “As we embark on a decade of national renewal, the higher education sector has a profound role to play in every piece of work we’ll need to do, to build a Britain that delivers for working people: from seizing the potential of clean energy to rebuilding the NHS.
“I will always champion our universities. They are society’s most powerful engines for innovation, aspiration, economic growth and the creation of better lives for all – which is why investing in their work, like this £30 million in funding, is so important.”
Science minister Lord Vallance told the PA news agency the research is “deeply impressive”.
He said: “I don’t know what they’re going to discover, but that’s the whole point.
“They’re going to discover new things that can’t be predicted and they are going to do that in a way that’s high quality and accessible for others to see.”
Lord Vallance added: “They’re a very high-quality team, they track some of the best researchers to come to the University of Dundee.
“And, of course, because of what they discover and the way they make it available to the industry, there’s also an important economic benefit.
“They create growth and they create wealth creation, so I think it’s a pretty impressive set-up they’ve got in Dundee.”
READ MORE:
- Skin tightening Sylfirm X microneedling: What is it like?
- £705k funding granted to Scots Uni project to identify cancer earlier
He said how cells communicate is a “fundamental question about what goes wrong” in terms of disease.
“This unit has been at the forefront of trying to understand that by looking at proteins and how proteins are modified,” he said.
“So it is carrying messages that have led to the identification of new ways of treating diseases.
“It has been used for Parkinson’s disease, it’s been used for cancers, it’s going to be important in other diseases in future.”
The new drug for Parkinson’s, created alongside partner organisations, is currently undergoing clinical trials.
Professor Patrick Chinnery, executive chairman of the MRC, said: “The MRC are proud to be investing for a further five years in the exceptional research of the MRC PPU in Dundee.
“They are leaders in conducting rigorous fundamental research and then working with industry to translate those breakthroughs for patient benefit.
“The MRC PPU have an outstanding culture of collaboration and sharing their leading research expertise, products and techniques with the wider scientific community.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here